Company Overview
Danaher Corp is a U.S.-based company in the Life Sciences Tools & Services industry. It develops and supplies instruments and consumables used in research, diagnostics, and production environments. The company’s portfolio spans multiple scientific and healthcare applications. Its market capitalization is approximately USD 134 billion.
Analysis of recent data
FundamentalsDanaher reported USD figures for 2025 with revenue of about 24.6 billion, representing 2.9% year‑over‑year growth. Depreciation and amortization were 750 million, and capital expenditures reached 1.16 billion. EBIT and net income were not provided, limiting visibility into full profitability. The total debt line showed 4 million, while cash was not disclosed.
On a trailing basis, the company’s gross margin stood at 59.23% and operating margin at 19.13%, indicating strong cost control. The net profit margin of 14.71% and ROE of 6.99% suggest moderate returns on equity. With a beta of 0.93, the stock shows slightly lower volatility than the broader market.
Valuation
DCF / MultiplesAt a share price of 189.37 USD, Danaher trades at 37.05 times trailing earnings and 5.45 times sales. The DCF analysis indicates a fair value well below the current market level, implying investors are paying for durability and consistency rather than near‑term growth. The high gross margin of 59.23% supports the view that the market values its resilience more than its expansion potential.
Conclusion
TakeawayDanaher appears to be valued for its reliability rather than rapid growth. The company’s strong margins show operational discipline. Missing earnings details make it harder to gauge true profitability. If growth slows, the current valuation could face pressure.